Phenytoin: Nursing Drug Guide, Level Monitoring & Toxicity
Phenytoin controls tonic-clonic seizures, but nursing safety hinges on therapeutic serum levels (usually 10–20 mcg/mL) and catching dose-related toxicity—ataxia, nystagmus, and confusion when levels climb—plus the boxed warning that IV infusion must not exceed 50 mg/min because of severe hypotension and cardiac arrhythmias. Pair level checks with neuro assessment and cardiac monitoring on every IV load.
Boxed warning: IV phenytoin must not exceed 50 mg per minute in adults (1–3 mg/kg/min or 50 mg/min, whichever is slower, in pediatric patients) because of risk of severe hypotension and cardiac arrhythmias. Continuous cardiac monitoring is required during and after infusion. Separately, serum levels sustained above the therapeutic range may cause nystagmus, ataxia, slurred speech, and confusional states; at the first sign of acute toxicity, check the level immediately and reduce or stop therapy per prescriber.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before every dose when levels are due or toxicity is suspected: assess gait, speech, and level of consciousness; trend phenytoin level against the 10–20 mcg/mL target; on IV loads verify pump rate ≤50 mg/min with cardiac monitoring. Hold and escalate when nystagmus, ataxia, or confusion appear with a high or rising level.
Most common brand names
Phenytoin is the generic name in most orders.
Common brands: Dilantin (extended phenytoin sodium capsules), Phenytek, generic phenytoin sodium capsules and oral suspension. IV products are labeled phenytoin sodium injection. Verify whether the order is immediate-release capsule, extended-release capsule, suspension, or IV—bioavailability, peak timing, and sodium vs free-acid content differ.
Why we give it — Indications
Phenytoin is a hydantoin antiepileptic drug for tonic-clonic and partial seizures in epilepsy and for status epilepticus when IV therapy is required. It is not indicated for absence (petit mal) seizures per labeling.
| Use | Nursing relevance |
|---|---|
| Generalized tonic-clonic (grand mal) epilepsy | First-line or adjunct therapy; levels often guide dose adjustments |
| Partial (focal) seizures | May be used alone or with other AEDs—interaction and level surveillance intensify |
| Status epilepticus (IV) | Loading dose 10–15 mg/kg adult at ≤50 mg/min; benzodiazepine or barbiturate often needed first because phenytoin must be given slowly |
| Seizure prophylaxis during neurosurgery | IV route when oral therapy is not possible; cardiac monitoring mandatory |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Phenytoin blocks voltage-dependent sodium channels, reducing sustained high-frequency neuronal firing. It is highly protein bound and metabolized by hepatic CYP2C9 (and to a lesser extent CYP2C19) with saturable (zero-order) kinetics at therapeutic doses—small dose increases can cause disproportionate level rises. Phenytoin is a potent enzyme inducer, lowering levels of many co-medications including oral contraceptives and warfarin.
DailyMed states therapeutic effect without clinical toxicity occurs most often with total serum concentrations between 10 and 20 mcg/mL (unbound 1–2 mcg/mL). Trough levels guide efficacy; peak levels help identify dose-related side effects. In renal or hepatic impairment or hypoalbuminemia, unbound (free) phenytoin levels may be more clinically relevant.
Dosing overview
Dosing is individualized using clinical response and serum levels. Oral phenytoin should be used whenever possible; IV is reserved for status epilepticus, perioperative use, or when oral administration is impossible.
Missed dose: Per DILANTIN patient counseling, take the missed dose as soon as remembered unless it is almost time for the next dose—then skip the missed dose and take the next dose at the regular time. Do not take two doses at once. Once-daily extended-release schedules carry higher seizure risk if a dose is missed inadvertently.
Dosing must be verified against current prescribing information, prescriber order, renal/hepatic function, albumin, and local policy.
Before you give it — Safety check
Pretreatment checks
- Confirm indication, seizure type, and route (oral vs IV load vs maintenance)
- Review latest phenytoin level (trough preferred) and compare to 10–20 mcg/mL target
- Baseline complete blood count and liver function tests per prescriber
- For IV: verify large-gauge peripheral or central access, compatible diluent (normal saline only—no dextrose), and pump rate ≤50 mg/min
- Perform medication reconciliation for interacting AEDs, azoles, amiodarone, and oral contraceptives
Contraindications (DailyMed)
- Hypersensitivity to phenytoin, its ingredients, or other hydantoins
- Sinus bradycardia, sino-atrial block, second- or third-degree AV block, Adams-Stokes syndrome (IV use)
- History of prior acute hepatotoxicity attributable to phenytoin
- Concurrent delavirdine
Important interactions
| Drug / class | Effect | Nursing action |
|---|---|---|
| Carbamazepine, phenobarbital, rifampin | May lower phenytoin levels (CYP inducers) | Watch for breakthrough seizures; level check per prescriber |
| Fluconazole, amiodarone, isoniazid, cimetidine | May raise phenytoin levels (CYP inhibitors) | Monitor for nystagmus, ataxia, slurred speech, somnolence |
| Lamotrigine, valproate, oral contraceptives | Phenytoin may lower co-medication levels | Breakthrough seizures or contraceptive failure—verify backup methods |
| Warfarin | Phenytoin may increase or decrease warfarin effect over time | Notify prescriber/pharmacist; do not adjust anticoagulant without orders |
| Chronic alcohol (acute vs chronic) | Acute intake may raise levels; chronic abuse may lower levels | Assess alcohol use; trend level after pattern change |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Oral: Capsules (including extended-release), chewable tablets, or suspension per product. Extended-release Dilantin capsules should be swallowed whole when product requires it—confirm with pharmacist.
IV: Administer into a large peripheral or central vein through a large-gauge catheter at ≤50 mg/min in adults. Flush catheter with sterile saline before and after each dose. Dilute in normal saline only (minimum 5 mg/mL if infusing); do not mix with dextrose. Complete infusion within 1–4 hours; do not refrigerate mixture.
- Follow medication administration rights; independent double-check IV rate and total load dose
- Continuous ECG and blood pressure monitoring during and after IV phenytoin per labeling
- Do not give IM except when no alternative—erratic absorption and local necrosis risk
- Document exact dose, rate, level timing, and any held doses with prescriber notification
Unless a life-threatening reaction requires immediate discontinuation, plan gradual withdrawal with prescriber guidance to avoid increased seizure frequency or status epilepticus. Substitute with a non-hydantoin AED if rapid switch is needed for hypersensitivity.
Expected therapeutic response
- Reduced seizure frequency or termination of status epilepticus after appropriate loading and maintenance
- Total phenytoin level within prescriber target (often 10–20 mcg/mL) without toxicity signs
- Steady gait, clear speech, and baseline cognition between doses
- No hypotension, arrhythmia, or local IV site complications during infusion
Red flags — Stop and act
Hold phenytoin and obtain urgent prescriber/pharmacist direction when any of the following appear:
- New nystagmus, slurred speech, marked ataxia, or confusion—especially with level above range or rising trend
- IV infusion-related hypotension, bradycardia, arrhythmia, or cardiac arrest during or after phenytoin administration
- Purple discoloration, swelling, or pain distal to IV site (purple glove syndrome) or extravasation
- Any new rash with fever, facial swelling, or mucosal involvement (SJS/TEN/DRESS concern)
- Significant drop in WBC, platelets, or signs of hepatotoxicity (jaundice, dark urine, severe abdominal pain)
Adverse effects
| Adverse effect | Clinical context | Nursing response |
|---|---|---|
| Nystagmus, ataxia, slurred speech, confusion | Usually dose-related; nystagmus often near 20 mcg/mL, ataxia near 30 mcg/mL per labeling | Check level; hold or reduce dose per prescriber; fall precautions |
| IV cardiovascular toxicity | Boxed warning—hypotension, arrhythmias, cardiac arrest; can occur at recommended rates | Slow or stop infusion; emergency cardiovascular support per protocol |
| Gingival hyperplasia | Common with long-term use | Dental hygiene teaching; report gum bleeding or pain |
| SJS / TEN / DRESS | Discontinue at first rash unless clearly not drug-related | Hold drug; do not rechallenge if severe cutaneous reaction suspected |
| Hepatotoxicity / marrow suppression | May be part of hypersensitivity spectrum | Trend LFTs and CBC; stop if significant injury or cytopenia |
| Suicidal thoughts or behavior | Class warning for antiepileptic drugs | Screen mood; escalate behavioral changes per policy |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
Early overdose signs include nystagmus, ataxia, and dysarthria. Higher levels may cause tremor, lethargy, slurred speech, blurred vision, nausea, vomiting, coma, and hypotension. Labeling notes wide individual variation: nystagmus on lateral gaze usually appears near 20 mcg/mL, ataxia near 30 mcg/mL, dysarthria and lethargy above 40 mcg/mL.
Labeling guidance
- No known antidote—treatment is nonspecific and supportive
- Maintain airway, breathing, and circulation; monitor neurologic status continuously
- Hemodialysis may be considered because phenytoin is not completely protein bound
- Assess for co-ingested CNS depressants including alcohol
- Contact local poison control / medical toxicology and emergency services per facility protocol
Look-alike / sound-alike and error prevention
- Phenytoin vs fosphenytoin (Cerebyx) — different products, doses, and rates; fosphenytoin is dosed in phenytoin sodium equivalents (PE); never interchange without pharmacist verification
- Dilantin (brand) vs phenytoin sodium (generic) — confirm extended-release vs prompt-release formulation; do not substitute without pharmacy approval
- Phenytoin sodium vs phenytoin (free acid) — approximately 8% difference in drug content; level monitoring may be needed when switching salt forms
- IV rate errors — programming 50 mg/min as 50 mL/min or confusing total load with hourly rate has caused cardiovascular collapse; use independent double-check
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Level timing | Draw trough before morning dose when possible; allow 5–7 half-lives after dose change before interpreting steady state |
| IV load math | 70-kg adult at 15 mg/kg = 1050 mg → minimum ~21 minutes at 50 mg/min; never rush the infusion |
| Neuro check | Ask patient to walk heel-to-toe and track speech clarity—early toxicity cues before lab returns |
| Gum care | Teach flossing and dental visits; gingival hyperplasia is common and may affect compliance |
| Formulation changes | Switching brands or salt forms without level recheck risks subtherapeutic or toxic levels |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Elderly or critically ill patients | Higher risk of IV cardiovascular toxicity; lower or less frequent dosing may be required |
| Renal/hepatic impairment or hypoalbuminemia | Monitor unbound (free) phenytoin levels; total level may mislead |
| CYP2C9 poor metabolizers | May develop higher levels at standard doses—watch early toxicity cues |
| Asian ancestry (HLA-B*1502 / CYP2C9*3) | Increased SCAR risk; consider avoiding as carbamazepine alternative when genetically at risk |
| Pregnancy | Can cause fetal harm and fetal hydantoin syndrome—specialist counseling; level monitoring during pregnancy |
| Lactation | Transferred to milk per labeling; LactMed notes infant monitoring if breastfeeding continues |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Phenytoin serum level (trough before next dose; peak when toxicity suspected) — target often 10–20 mcg/mL total
- Neurologic exam: nystagmus, gait, speech, cognition, and dizziness each shift when levels are unstable
- During IV therapy: continuous ECG, blood pressure, and respiratory status per labeling
- IV site for extravasation, purple discoloration, or pain distal to catheter
- CBC and LFTs at baseline and when cytopenia or hepatotoxicity suspected
- Seizure frequency and mood/suicidal ideation per antiepileptic drug class warning
Document
- Level results with timing relative to last dose (trough vs random)
- IV rate (mg/min), total load delivered, and any rate reductions for hypotension
- Hold actions and prescriber/pharmacist notifications for toxicity or rash
- Patient teach-back on reporting unsteady gait, slurred speech, or vision changes
Patient teaching
- Take at the same times each day; do not skip doses or double up without prescriber guidance
- Report unsteady walking, slurred speech, double vision, excessive sleepiness, or confusion—these may mean the level is too high
- Report any new rash, fever, or facial swelling immediately
- Maintain dental hygiene and regular dental visits because gum enlargement is common
- Do not stop suddenly—withdraw gradually unless emergency reaction
- Hormonal contraceptives may be less effective—discuss backup methods with prescriber
- Report depression, suicidal thoughts, or unusual mood changes promptly
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Phenytoin level above institutional hold threshold or clinical toxicity (nystagmus, ataxia, slurred speech, confusion) with high or rising level
- Hypotension, bradycardia, or arrhythmia during or immediately after IV phenytoin
- IV extravasation, purple glove syndrome signs, or severe local pain
- Any new rash unless prescriber documents clearly not drug-related; hold for suspected SJS/TEN/DRESS
- Significant drop in WBC/platelets or clinical hepatitis
Hold parameters can vary by institution. Follow prescriber orders, pharmacy guidance, and local policy.
Clinical practice integration and workflow
Phenytoin harm usually comes from unrecognized level toxicity or IV rate errors. Build level-and-neuro surveillance into every pass, and treat the 50 mg/min ceiling as non-negotiable unless prescriber and pharmacy document an exception.
1. Check-before-you-give protocol
- Review latest phenytoin level and time of last dose
- Assess gait, speech, nystagmus, and cognition
- For IV: verify programmed rate ≤50 mg/min and patency of large-bore access
- Confirm formulation matches MAR (extended vs prompt capsule; IV vs oral)
2. High-alert and safety badge
IV cardiovascular risk — max 50 mg/minOral phenytoin is not on every institutional high-alert list, but IV phenytoin carries a boxed warning for severe hypotension and arrhythmias—treat IV loads with the same rigor as high-alert medication workflows.
3. Clinical workflow: hold and question rules
- If nystagmus or ataxia appears with level ≥20 mcg/mL, hold and notify before next dose
- If BP drops during IV load, slow or stop infusion and notify prescriber immediately
- After any formulation or salt-form switch, recheck level before assuming prior dose remains safe
4. Critical teach-back questions
- “What body changes mean your phenytoin level may be too high?” (Unsteady walking, slurred speech, double vision, excessive sleepiness.)
- “Can you stop this seizure medicine suddenly?” (No—unless emergency reaction; otherwise taper per prescriber.)
5. Care coordination
Pharmacist: Level interpretation (total vs free), interaction checks, formulation and IV rate verification
Neurology / prescriber: Seizure plan if drug held; alternative AED selection; gradual withdrawal orders
🧠 Quick mental checklist
- Level due or above 20 mcg/mL with new nystagmus or unsteady gait?
- IV pump set ≤50 mg/min with ECG monitoring active?
- Speech, cognition, and gait aligned with last level?
- Correct capsule type and no fosphenytoin/phenytoin mix-up?
- Patient can name the symptom that means “hold and call”?
Phenytoin NCLEX practice questions
Rehearse NCLEX-style clinical judgment practice for phenytoin using a tabbed case panel (MAR, labs, vitals, nursing notes), then priority action, SATA toxicity cues, level trend interpretation, matrix urgency judgment, IV rate MCQ, and overdose cloze—focused on therapeutic level monitoring, dose-related toxicity, and the ≤50 mg/min IV boxed warning.
Select a tab to view MAR, labs, vitals, and nursing note details for this case.
- Phenytoin 100 mg PO q8h (maintenance after 1 g IV load 5 days ago)
- Fluconazole 200 mg PO daily (started 2 days ago for oral candidiasis)
- Acetaminophen 650 mg PO q6h PRN pain
- Normal saline 0.9% IV at 75 mL/h via peripheral line
- Post-load day 1: phenytoin level 18.2 mcg/mL
- Post-load day 3 (pre-fluconazole): phenytoin level 16.4 mcg/mL
- Today (fluconazole day 2): phenytoin level 24.6 mcg/mL; ALT 42 U/L; WBC 7.0 K/uL
- BP 118/72, HR 88, RR 16, SpO2 98% on room air
- Alert but slow to respond; slurred speech noted this shift
- Gait wide-based; horizontal nystagmus on lateral gaze
- No seizure activity this shift
- Patient reports “feeling drunk” and bumped into bed rail walking to bathroom
- 0900 phenytoin dose given; 1700 dose due
- Fluconazole started without pharmacy level review per night admission note
- Family asks why speech is different since yesterday
Answer key & rationale
Frequently asked questions
What phenytoin level range is considered therapeutic?
DailyMed states therapeutic effect without clinical toxicity occurs most often with total serum concentrations between 10 and 20 mcg/mL (unbound 1–2 mcg/mL). Some patients may be controlled below this range; unbound levels may be more relevant with renal or hepatic impairment or hypoalbuminemia.
What are early signs of phenytoin toxicity?
Dose-related nervous system effects include nystagmus, ataxia, slurred speech, decreased coordination, somnolence, and mental confusion. Labeling notes nystagmus on lateral gaze usually appears near 20 mcg/mL and ataxia near 30 mcg/mL, with wide individual variation.
Why must IV phenytoin not exceed 50 mg per minute?
The boxed warning states IV administration must not exceed 50 mg per minute in adults because of risk of severe hypotension and cardiac arrhythmias. Continuous ECG and blood pressure monitoring is required during and after infusion.
Is there an antidote for phenytoin overdose?
No known antidote is listed. Care is supportive with attention to respiration and circulation; hemodialysis may be considered. Use local poison control per protocol.
Can phenytoin be stopped abruptly in epilepsy?
Labeling warns abrupt discontinuation may increase seizure frequency including status epilepticus. Taper gradually unless an urgent hypersensitivity reaction requires rapid switch to a non-hydantoin AED.
What is the difference between phenytoin and fosphenytoin?
Fosphenytoin is a prodrug converted to phenytoin with different dosing in phenytoin sodium equivalents. Do not interchange products or rates without pharmacist verification.
References
- U.S. National Library of Medicine. PHENYTOIN SODIUM injection — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=035a8d4e-2063-4240-83cb-d7eebcabe301
- U.S. National Library of Medicine. DILANTIN (extended phenytoin sodium capsules) — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=86dd27d1-9cee-48ae-b55d-e2d2f7dbc593
- Drugs and Lactation Database (LactMed). Phenytoin. Bethesda (MD): National Institute of Child Health and Human Development.https://www.ncbi.nlm.nih.gov/books/NBK501402/
- U.S. Food and Drug Administration. Suicidal thoughts and behavior in patients taking antiepileptic drugs.https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-suicidal-thoughts-and-behavior-antiepileptic-drugs
- National Institute for Health and Care Excellence (NICE). Epilepsies: diagnosis and management — Phenytoin. BNF/NICE.https://bnf.nice.org.uk/drugs/phenytoin/
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.